NYSE:CRISPR Therapeutics AG

График котировок CRISPR Therapeutics AG

Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/E 124.34
P/S 167.98
P/BV 10.6
EV/EBITDA -56.74
EBITDA -0.23
Цена ао 199.88

Основные владельцы

Institutions Объем Доля, %
Versant Venture Management LLC 3631656 5.1
First Trust Portfolios L.P. 35210 0.05
Financial Trust Asset Management 730 0
Emerge Canada Inc. 23802 0.03
Peroni Portfolio Advisors, Inc 500 0
Abingworth LLP 259599 0.36
Global X Management Company LLC 49667 0.07
Exchange Traded Concepts, LLC 28874 0.04
American Beacon Advisors Inc 293953 0.41
Nikko Asset Management Co Ltd 1010300 1.42
BlackRock Fund Advisors 729789 1.02
NEA Management Company, LLC 1590002 2.23
Middlefield Capital Corporation 30000 0.04
Shelton Capital Management 64000 0.09
Saint Olive Gestion 65000 0.09
Nikko AM Limited 57018 0.08
Delaware Management Company 471129 0.66
Massachusetts Institute Of Technology 22162 0.03
Invesco Capital Management LLC 99216 0.14
Millington Securities, Inc. 26761 0.04
Middlefield Limited 20000 0.03
Columbia Wanger Asset Management LLC 643047 0.9

Содержится в ETF

ETF Доля, % Доходность за год, %
ARK Innovation ETF 5.34 176.62
ARK Genomic Revolution ETF 4.73 221.65
iShares Genomics Immunology and Healthcare ETF 4.75 77.60
Global X Genomics & Biotechnology ETF 5.99 69.62
Loncar Cancer Immunotherapy ETF 4.08 50.95
ERShares Non-US Small Cap ETF 5.31 48.34
Franklin Genomic Advancements ETF 6.01
iShares Morningstar Small-Cap Growth ETF 1.26 51.98
Principal Healthcare Innovators Index ETF 1.72 65.90
Entrepreneur 30 Fund 5.01 56.52
BNY Mellon US Small Cap Core Equity ETF 0.41
Invesco DWA Healthcare Momentum ETF 3.91 87.65
VictoryShares US 500 Enhanced Volatility Weighted ETF 0.3 21.34
VictoryShares US 500 Volatility Weighted Index ETF 0.3 13.40
Timothy Plan US Large Cap Core ETF 0.45 15.94
Virtus LifeSci Biotech Clinical Trials ETF 0.75 43.09
Invesco PureBetaSM MSCI USA Small Cap ETF 0.24 27.86

Похожие компании

Описание CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)\u002FCRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.